NCT04620187 - Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 24, 2020

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2027

Conditions

Salivary Gland CancerHER2 Gene Mutation

Interventions

DRUG

Ado-trastuzumab (T) emtansine (T-DM1)

Intravenous infusion ever 21 days (3weeks) for 1 year (52 weeks)

RADIATION

Standard of Care Radiotherapy

Radiotherapy to shrink or kill tumors

DRUG

Standard of Care Chemotherapy

Intravenous injection

Trial Locations (12)

10021

RECRUITING

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester, Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau, Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack, Commack

60637

RECRUITING

University of Chicago, Chicago

98195

RECRUITING

University of Washington Medical Center, Seattle

02115

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth, Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen, Montvale